Pharmacokinetics of Scopolamine Intranasal Gel Formulation (INSCOP) During Antiorthostatic Bedrest by Putcha, Lakshmi et al.
Pharmacokinetics of Scopolamine Intranasal 
gel Formulation (INSCOP) during 
Antiorthostatic Bedrest
L. Putcha1, J. L. Boyd2, B. Du3, V. Daniels4 and 
C. Crady4
1 NASA Johnson Space Center  Houston  TX, ,
2 Simulations Plus, Lancaster, CA
3 Prairie View A and M University, Prairie View, TX
4 W le Laboratories  Ho ston  TXy , u ,
1
https://ntrs.nasa.gov/search.jsp?R=20110011043 2019-08-30T15:29:19+00:00Z
Introduction
 Space Motion sickness (SMS) is an age old problem for space 
t l   h t d l  d ti   fli ht rave ers – on s or an ong ura on space g
 Oral antiemetics are not very effective in space due to poor 
bioavailability
 Scopolamine (SCOP) is the most frequently used drug by 
recreational travelers – patch, tablets available on the market
 Common side effects of antiemetics, in general, include 
drowsiness, sedation, dry mouth and reduced psychomotor 
performance  
 Severity and persistence of side effects are often dose related
 Side effects can be detrimental in high performance demanding 
settings, e.g. space flight, military
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The Oral Scopolamine Story
A representative saliva 
concentration –time 
profile in a crewmember
Mean Plasma concentration –
time curve in normal 
subjects 
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Intranasal Scopolamine
 Oral, injectable and transdermal  formulations of SCOP are either 
invasive, unsuitable or ineffective for the treatment of SMS
 I l d  f  f l i  ff   i  f  h  ntranasa osage orm o scopo am ne o ers great prom se or t e
treatment  of MS on Earth and in space
 Advantages of intranasal dosage forms in general are:
 Noninvasive
 Rapid absorption facilitating rescue and treatment options with 
the same formulation
 Enhanced  and reliable bioavailability allowing precise and 
reduced dosing options
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A First Step - INSCOP Drops Formulation 
Development
Results from a Phase I IND study showed 83% bioavailability of INSCOP 
versus 3.7% bioavailability of oral SCOP
Study Population: 12 healthy male 
subjects 
Study Design: Randomized 
Crossover Design 
Treatments: 0.4 mg of IV, PO, or 
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Blood Samples: Pre-dose, 0.42, 
0.83, 0.17, 0.33, 0.50, 0.75, 1, 
1.5, 2, 3, 4, 5, 6, 8, 10, 12hr 
post dose.
C
o
n
c
e
n
Putcha L, Tietze KJ, Bourne DW, Parise CM, Hunter RP, Cintron NM. Bioavailability of intranasal scopolamine 
Time (h)
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in normal subjects. J Pharm Sci. 1996 Aug;85(8):899-902.
Requirements for Therapeutics in Space
 Medications used for treatment in space must be 
commercial products for efficacy and safety 
reasons
 Investigational New drug (IND) protocols must 
strictly adhere to  FDA guidelines for conducting 
Phase I - IV clinical trials to establish efficacy  ,
safety and commercial potential
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Pharmacotherapeutics of Intranasal Scopolamine –
A NSBRI sponsored Drug Development project of 
INSCOP
Four FDA sponsored clinical trials were designed to characterize 
pharmacokinetics (PK) and pharmacodynamics, and evaluate the safety and 
efficacy of INSCOP
SPECIFIC AIMS FDA PROTOCOL
Specific Aim # 1: Establish PK of INSCOP with three 
escalating dose levels of 0.1, 0.2 and 0.4 mg 
INSCOP 002-A: Dose 
Ranging PK Study (MDS)
D / Effi  St di
Specific Aim # 2: Perform a dose ranging Efficacy 
study of INSCOP 
ose cacy u es:
INSCOP 002-B 
(Dartmouth)
INSCOP 002-D (NAMRL)
Specific Aim # 3: Determine if bioavailability and PD 
of IN SCOP are altered in a simulated microgravity 
INSCOP 002-C: 
Bioavailability Study 
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environment during ABR (MDS)
Specific Aim #1: Protocol 002-A
A Phase I, Randomized, Double-Blind, Placebo-
Controlled, Dose Ranging Study of Pharmacokinetics 
and Pharmacod namics of Intranasal Scopolaminey
 Dose escalation of INSCOP at 0.1, 0.2 and 0.4 mg dose 
levels
 12 normal healthy subjects (6 male/6 female) received 
INSCOP in a placebo-controlled randomized crossover 
design
 Assessment of primary PK parameters of INSCOP as a 
function of dose
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Results
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Specific Aim #2: Protocol 002-B
A Phase II, Randomized, Double-Blind, Placebo-
Controlled, Efficacy Study of Intranasal Scopolamine
 Clinical efficacy study with 0.2 and 0.4 mg and INSCOP 
given as pre-treatment for motion sickness induced by 
off-axis Vertical Rotation Chair (VRC)
 18 male/ female, motion sickness susceptible subjects
 Establish concentrations of INSCOP for efficacy as well 
  PK (10 bj t  ONLY) f th  t  d  f as assess su ec s o e wo oses o
INSCOP 
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Specific Aim #3: Protocol 002-C
A Phase II, Randomized, Double-Blind, Bioavailability 
Study of Intranasal Scopolamine in a Simulated 
Microgravity Environment
 Estimate the bioavailability of a 0.2 mg dose and 0.4 mg 
dose of INSCOP during ambulation (AMB) and simulated 
microgravity  Antiorthostatic Bed Rest (ABR),
 12 normal healthy subjects (6 male/ 6 female) received 
INSCOP i   f   d in a our-way crossover es gn
 Evaluate PK/PD, safety and side effect profile of the two 
doses during AMB vs. ABR
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Results
Concentration – time profiles of scopolamine in 
lp asma
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Primary PK Parameters
Dose(mg)
Parameters   
(Mean±SE)    Units 0.2 0.4
AMB ABR AMB ABR
Cmax/D pg/ml*mg 2.24±0.30 2.25±0.27 1.99±0.27 2.43±0.26*
Tmax h 1.27±0.23 0.83±0.06 1.04±0.18 0.96±0.11
AUCinf/D h*pg/mL*mg 9.02±1.72 7.81±1.14 7.14±1.49 9.47±1.66**
Vs L 578.03±93.55 545.96±49.82 568.90±75.37 773.91±209.35
Cls L/h 141.70±16.45 156.36±20.22 180.70±22.40 128.20±14.01*
t½ h 3.23±0.56 2.80±0.33 3.14±1.26 5.02±1.41
*P 0 0
14
< . 5
**P<0.005
Comparative Profiles
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PK Results (002 A)
 Dose-related nonlinearity between 0.2 and 0.4 with 
clinically significant primary PK parameters, Cmax and 
AUC
 Dose and dosing intervals may be adjusted to account 
for nonlinearity at higher doses
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PK Results (002 C) 
 No difference between AMB and ABR in PK parameters after 
0 2  d  . mg ose
 Cls decreased with a concomitant increase in Cmax and AUC 
during ABR after 0 4 mg dose.
 This difference in AUC and Cls at the higher but not the 
lower dose during ABR is in agreement with the nonlinear 
kinetics with dose observed at these doses (002 A)
 Dosing adjustment may be required for treatment with 
INSCOP in space
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Overall Results
 Inter-site differences in profiles – may be a result of 
dosing discrepancies between study sites
 The dosage form for A and B are from a different 
d   h  f  Cven or t an or
 Data for all protocols ( 0.2 and 0.4 ambulatory) will be 
pooled for obtaining statistical rigor for modeling
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Data Analysis in Progress
Extremely Rich data facilitating complex analysis 
options – Some trend analysis and interpretation currently in 
progress with respect to:
PK
• Gender differences
• Dose – related metabolism differences
• PK modeling combining all ambulatory subjects data
• Plasma/saliva simultaneous fitting and correlation
• Metabolite kinetics
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Data Analysis in Progress
PD Dose – Effect analysis with 
 BP, HR data
 ARES Performance Parameters 
Reaction time
Accuracy
Short and running memory recall
PK/PD Modeling with applicable response parameters
Stay tuned for next update!
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